The applicant’s CCT model directly targets addiction‑related neural encoding, aligning with ATN’s focus on novel brain‑disease therapies. Their computational neuroscience and pharmacology expertise, plus strong collaborations with leading labs, make them a strong early‑career candidate for the two‑year industry‑sponsored joint project.